Last 48 quarters of trend data · Healthcare · Medical - Devices
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
Avanos Medical, Inc.'s quarterly P/E stands at 31.8x, up 24.4% year-over-year — indicating the stock has re-rated higher or earnings have softened. EV/EBITDA has compressed 10.5% YoY to 9.5x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -16.97 | 31.84 | 35.23 | — | — | 25.59 | — | 65.09 | 127.04 | — | 24.38 | — | — |
| — | +24.4% | — | — | — | — | — | — | — | — | +29.7% | — | — | |
| P/S Ratio | 1.65 | 0.89 | 0.72 | 0.75 | 0.82 | 1.00 | 1.02 | 1.64 | 1.34 | 1.38 | 1.51 | 1.38 | 1.77 |
| — | -10.9% | -29.4% | -54.1% | -39.1% | -27.7% | -32.4% | +19.0% | -23.9% | -36.3% | -13.9% | -7.0% | -7.3% | |
| P/B Ratio | 1.48 | 0.83 | 0.67 | 0.69 | 0.74 | 0.80 | 0.88 | 0.91 | 0.75 | 0.75 | 0.85 | 0.77 | 0.97 |
| — | +4.0% | -24.2% | -24.3% | -2.2% | +6.7% | +4.5% | +17.6% | -22.1% | -29.8% | -14.2% | -4.4% | -6.8% | |
| P/FCF | 26.91 | — | 6.12 | 19.16 | — | 8.82 | 3.45 | 14.00 | 10.53 | — | 38.43 | 9.39 | — |
| — | — | +77.4% | +36.9% | — | — | -91.0% | +49.1% | — | — | +248.1% | -15.3% | — | |
| EV / EBITDA | — | 9.46 | — | 6.66 | 8.96 | 10.57 | 8.42 | 10.85 | 9.57 | 14.08 | 8.65 | 7.85 | 15.48 |
| — | -10.5% | — | -38.6% | -6.4% | -24.9% | -2.7% | +38.3% | -38.2% | -41.0% | -29.8% | -35.2% | -9.7% | |
| EV / EBIT | — | — | 45.19 | 249.83 | — | 15.14 | — | 24.27 | 28.18 | 57.54 | 23.91 | 136.42 | — |
| — | — | — | +929.3% | — | -73.7% | — | -82.2% | — | — | +16.4% | +490.3% | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Avanos Medical, Inc.'s operating margin was 4.9% in Q1 2026, up 54.2 pp QoQ and up 0.5 pp YoY. The trailing four-quarter average of -8.2% lags the current quarter, suggesting the recent improvement is above-trend. Gross margin contracted 3.6% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 49.8% | 51.7% | 47.5% | 45.6% | 52.6% | 53.6% | 55.3% | 54.5% | 55.7% | 57.1% | 54.8% | 55.8% | 57.7% |
| — | -3.6% | -14.0% | -16.3% | -5.5% | -6.1% | +0.9% | -2.2% | -3.6% | -0.5% | -3.3% | -4.1% | -2.9% | |
| Operating Margin | -8.8% | 4.9% | -49.4% | 7.4% | 4.2% | 4.4% | 7.0% | 9.8% | 9.4% | 4.5% | 12.8% | 14.9% | 7.0% |
| — | +12.1% | -809.3% | -24.8% | -55.5% | -2.2% | -45.7% | -34.2% | +34.6% | +29.0% | +33.7% | +71.0% | +0.9% | |
| Net Margin | -9.7% | 2.8% | 2.0% | -0.8% | -43.9% | 3.9% | -221.2% | 2.5% | 1.0% | -0.5% | 6.1% | -2.2% | -40.2% |
| — | -29.0% | +100.9% | -131.2% | -4286.4% | +827.3% | -3751.1% | +216.8% | +102.6% | -72.6% | -34.9% | -123.7% | -649.6% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -8.5% | 0.7% | 0.5% | -0.2% | -9.5% | 0.8% | -38.6% | 0.4% | 0.1% | -0.1% | 0.9% | -0.3% | -5.4% |
| — | -17.4% | +101.2% | -151.3% | -6571.5% | +1184.1% | -4619.6% | +216.5% | +102.7% | -89.1% | -35.4% | -124.1% | -639.3% | |
| ROA | -6.1% | 0.5% | 0.3% | -0.1% | -7.2% | 0.6% | -28.3% | 0.3% | 0.1% | -0.1% | 0.6% | -0.2% | -4.0% |
| — | -17.7% | +101.2% | -151.2% | -6694.3% | +1186.8% | -4701.1% | +218.9% | +102.7% | -89.1% | -35.2% | -124.5% | -663.6% | |
| ROIC | -5.4% | 0.8% | -8.1% | 1.2% | 0.6% | 0.6% | 0.8% | 0.9% | 0.9% | 0.4% | 1.2% | 1.4% | 0.6% |
| — | +29.4% | -1062.2% | +26.8% | -27.9% | +51.5% | -29.9% | -31.2% | +44.0% | +43.1% | +32.7% | +74.4% | +1.6% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Avanos Medical, Inc.'s Debt/EBITDA ratio is 7.2x — elevated, raising questions about debt serviceability.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.17 | 0.18 | 0.17 | 0.17 | 0.18 | 0.17 | 0.21 | 0.16 | 0.18 | 0.17 | 0.17 | 0.25 | 0.21 |
| — | +5.4% | -19.2% | +4.5% | -1.0% | -4.0% | +21.5% | -34.5% | -13.1% | -11.1% | -21.2% | +4.2% | -15.9% | |
| Debt / EBITDA | — | 7.25 | — | 5.94 | 7.94 | 8.34 | 7.21 | 7.12 | 7.97 | 11.42 | 6.20 | 8.40 | 11.49 |
| — | -13.1% | — | -16.5% | -0.4% | -27.0% | +16.2% | -15.3% | -30.7% | -27.6% | -35.5% | -30.9% | -17.8% | |
| Current Ratio | 2.15 | 2.48 | 2.15 | 2.38 | 2.64 | 2.57 | 2.37 | 2.22 | 2.28 | 2.28 | 2.08 | 3.07 | 3.16 |
| — | -3.6% | -9.3% | +7.0% | +16.1% | +12.7% | +14.2% | -27.8% | -27.9% | -20.4% | -36.5% | +6.1% | +9.2% | |
| Quick Ratio | 1.26 | 1.40 | 1.26 | 1.36 | 1.58 | 1.56 | 1.53 | 1.46 | 1.49 | 1.47 | 1.38 | 2.16 | 2.23 |
| — | -10.4% | -18.2% | -7.0% | +6.4% | +6.1% | +11.2% | -32.3% | -33.3% | -8.0% | -46.4% | +26.6% | +25.9% | |
| Interest Coverage | -15.55 | 5.93 | 1.63 | 0.33 | -36.95 | 5.62 | -149.18 | 3.97 | 3.00 | 1.48 | 3.70 | 0.45 | -0.46 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare business quality, growth, and profitability against top sector peers.
Start ComparisonQuick answers to the most common questions about buying AVNS stock.
Avanos Medical, Inc.'s current P/E is -17.0x. The average P/E over the last 2 quarters is 33.5x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Avanos Medical, Inc.'s current operating margin is -8.8%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Avanos Medical, Inc.'s business trajectory between earnings reports.